Glenmark Pharmaceuticals Inc., USA (Glenmark) and Glenmark Pharmaceuticals have reached a settlement agreement with Pfizer
Inc., PF Prism C.V., and PF Prism IMB B.V. (Pfizer) for Axitinib Tablets, 1 mg and 5 mg, the generic version of their Inlyta1 Tablets, 1 mg and 5 mg.
Glenmark had previously announced it received tentative approval by the United States Food & Drug Administration (USFDA) for their generic Axitinib Tablets, 1 mg and 5 mg on 30 November 2020.
According to IQVIATM sales data for the 12‐month period ending September 2022, the Inlyta Tablets, 1 mg and 5 mg market achieved annual sales of approximately $644.5 million.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
